AngioVue Retina is configured with essential OCTA and OCT features designed specifically for retinal practices to allow adoption of OCT and OCTA into the clinical workflow with minimal disruption.

"By adding AngioVue Retina to our product portfolio, we are able to help retinal physicians acquire OCTA technology in a cost-efficient manner thereby adding this technology to their armamentarium of diagnostic imaging tools," said John Hawley, senior vice president of Global Sales for Optovue.

"OCTA imaging is in its nascent phase and we expect applications to rapidly unfold over the next few years. As such, we are pleased to offer this important technology in different product configurations that meet the needs of all ophthalmology practices."

Optovue’s AngioVue Retina provides retinal specialists with the ability to quickly visualize the presence or absence of retinal vessels and assess new information about the microvasculature with extraordinary detail.

This information may be integrated with other diagnostic imaging results to form a complete picture of a patient’s disease state and their treatment options.

The company also announced its new DualTrac Motion Correction for use with both the AngioVue and AngioVue Retina systems, a two-level approach to correcting motion artifacts resulting from patient movement.

The first level provides real-time correction for rapid eye movements, blinking or eye drifting. The second level occurs during imaging post-processing and corrects smaller levels of motion distortion.

This combined approach results in robust motion correction for patients who have trouble directing their focus on a central point during an eye exam, which is essential for high quality OCTA imaging.

Optovue recently received FDA clearance for its AngioVue Imaging System, bringing the significant benefits of non-invasive retinal imaging to patients in the U.S. who suffer from diseases that lead to progressive blindness.

In addition to retina applications, the AngioVue System is a comprehensive platform that addresses other ophthalmology applications such as imaging the front of the eye and the optic nerve. The AngioVue System first received regulatory clearance for use outside the US in 2014.